If genome sequencing is performed in health care, in theory the opportunity arises to take a
further look at the data: opportunistic genomic screening (OGS). The European Society of …

As the use of genomic sequencing (GS) in the prenatal setting becomes more widespread,
laboratories and clinicians will be tasked with making decisions about whether to offer …

Objective To support informed decision-making about reanalysis of clinical genomic data for
risk of preventable conditions ('additional findings') by developing a chatbot (electronic …

Increasing use of diagnostic genomic sequencing is pushing health services to confront the
issue of opportunistic genomic screening (OGS). To date, OGS has been offered …

Introduction As routine genomic testing expands, so too does the opportunity to look for
additional health information unrelated to the original reason for testing, termed additional …

Germline genome sequencing (GS) holds great promise for cancer prevention by identifying
cancer risk and guiding prevention strategies, however research evidence is mixed …

Health economic evidence is needed to inform the design of high-value and cost-effective
processes for returning genomic results from analyses for additional findings (AF). This study …

Researchers and research participants increasingly support returning clinically actionable
genetic research findings to participants, but researchers may lack the skills and resources …

Purpose To evaluate the resource implications of different delivery models for the provision
of additional findings (AF) in genomics from a health-care purchaser perspective. Methods …

Abstract Background The Melbourne Genomics Health Alliance (the Alliance) is a
collaboration of leading hospitals, research and academic organisations, supported by its …